Dr. Palmer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 480-301-8000
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
New York Medical CollegeClass of 2001
Certifications & Licensure
AZ State Medical License 2013 - 2026
WI State Medical License 2008 - 2013
NY State Medical License 2003 - 2005
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
- Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Start of enrollment: 2021 Jan 14
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsMayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2025-02-01 - Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST-2 Landmark Analysis of Survival.Helen Ajufo, Jan Philipp Bewersdorf, Claire Harrison, Francesca Palandri, John Mascarenhas
European Journal of Haematology. 2025-02-01 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, Saubia Fathima, Kebede H Begna
American Journal of Hematology. 2025-01-28
Press Mentions
CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 11th, 2022- Pacritinib Approved for Intermediate- or High-Risk Myelofibrosis with ThrombocytopeniaMarch 3rd, 2022
Fighting Leukemia Then Joining the TeamAugust 2nd, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
